Matches in Wikidata for { <http://www.wikidata.org/entity/Q91809258> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- Q91809258 description "article scientifique publié en 2020" @default.
- Q91809258 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91809258 description "scientific article published on 07 April 2020" @default.
- Q91809258 description "wetenschappelijk artikel" @default.
- Q91809258 description "наукова стаття, опублікована 7 квітня 2020" @default.
- Q91809258 description "գիտական հոդված հրատարակված 2020 թվականի ապրիլի 7-ին" @default.
- Q91809258 name "Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study" @default.
- Q91809258 name "Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study" @default.
- Q91809258 type Item @default.
- Q91809258 label "Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study" @default.
- Q91809258 label "Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study" @default.
- Q91809258 prefLabel "Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study" @default.
- Q91809258 prefLabel "Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study" @default.
- Q91809258 P1433 Q91809258-7993DF1C-F15F-43A0-8AFE-15266A64716E @default.
- Q91809258 P1476 Q91809258-65E80487-2F19-4AB2-94D0-2B30E9BA68FA @default.
- Q91809258 P2093 Q91809258-000F0B00-6B89-410F-A512-8DC7AC72EDB7 @default.
- Q91809258 P2093 Q91809258-0D9CA3E2-5EF1-4B9A-8EB8-90A90A69F03E @default.
- Q91809258 P2093 Q91809258-0F7F3713-951E-4352-81CC-B89C91A9C3BB @default.
- Q91809258 P2093 Q91809258-20E73517-2A22-4C9C-B7EC-823486FD73CD @default.
- Q91809258 P2093 Q91809258-3CFAEA16-FC20-4234-809D-084AB368DE0A @default.
- Q91809258 P2093 Q91809258-4057BC8B-D12B-43D1-8FC4-772EFDC8E904 @default.
- Q91809258 P2093 Q91809258-414139DF-396F-4A3B-9C9D-5F358FAB5B8B @default.
- Q91809258 P2093 Q91809258-4841A327-3309-406B-8D46-9FC5BAC84AC1 @default.
- Q91809258 P2093 Q91809258-555CFEEC-B69F-40C6-AB0C-536D1E0D9BDC @default.
- Q91809258 P2093 Q91809258-590054B5-9730-48DA-B3FE-B9B81954B279 @default.
- Q91809258 P2093 Q91809258-5AEA2221-D764-4641-99B0-51C2EB4CDA6E @default.
- Q91809258 P2093 Q91809258-670EC6E5-C9BB-4128-9BB6-590F71E06375 @default.
- Q91809258 P2093 Q91809258-75DDB20A-A012-4A8E-A5D3-568A55240266 @default.
- Q91809258 P2093 Q91809258-8C7BB7A5-DAD7-4775-BBC7-9F08C0197BB6 @default.
- Q91809258 P2093 Q91809258-8CC2C653-42CC-4D57-9ED3-D5967181CE2B @default.
- Q91809258 P2093 Q91809258-AB6C306F-7E75-4400-94CB-7E79E07E370C @default.
- Q91809258 P2093 Q91809258-AF0CD3C9-3B4E-467D-B68D-BBA0085E5A76 @default.
- Q91809258 P2093 Q91809258-B1E1B69D-3918-4D32-825B-714AE1EEA37F @default.
- Q91809258 P2093 Q91809258-B66FEB5C-A0F6-41D0-879D-9BB6FDE0F5D2 @default.
- Q91809258 P2093 Q91809258-BD3BD686-E7FE-4832-A742-533584F6BC2C @default.
- Q91809258 P2093 Q91809258-D913BFE1-D5B5-4682-9FC9-305CEC66497F @default.
- Q91809258 P2093 Q91809258-FC3D8EBD-4DFB-455E-9EF1-A51B5E7AC592 @default.
- Q91809258 P304 Q91809258-338E91BF-D3B2-4135-9225-8B1E5097308C @default.
- Q91809258 P31 Q91809258-C16398C4-4FF7-461B-BF04-164C816E5468 @default.
- Q91809258 P356 Q91809258-08B4B5B6-928C-455C-8598-3C9628C3433D @default.
- Q91809258 P478 Q91809258-A2857168-4E3C-4CED-B32A-BB428DAFEAB9 @default.
- Q91809258 P577 Q91809258-D2F3CBF9-5AFA-4C3D-A128-C17ADDCB7F28 @default.
- Q91809258 P698 Q91809258-BA3504D8-F5B5-4110-B498-1566C2664B32 @default.
- Q91809258 P921 Q91809258-0FC8A15C-9388-4481-9F77-E61FCC57BE83 @default.
- Q91809258 P921 Q91809258-1BBF801F-BE8C-4208-8CC1-F04716A1B338 @default.
- Q91809258 P921 Q91809258-2C861358-F384-454C-AC5F-79F36A702F7E @default.
- Q91809258 P356 J.EJCA.2020.02.022 @default.
- Q91809258 P698 32276179 @default.
- Q91809258 P1433 Q332260 @default.
- Q91809258 P1476 "Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study" @default.
- Q91809258 P2093 "Adrien Dixmier" @default.
- Q91809258 P2093 "Alexandra Langlais" @default.
- Q91809258 P2093 "Alexis B Cortot" @default.
- Q91809258 P2093 "Benjamin Besse" @default.
- Q91809258 P2093 "Catherine Becht" @default.
- Q91809258 P2093 "Charles Dayen" @default.
- Q91809258 P2093 "Claire Poulet" @default.
- Q91809258 P2093 "Clara Fontaine-Delaruelle" @default.
- Q91809258 P2093 "Clarisse Audigier-Valette" @default.
- Q91809258 P2093 "Damien Pouessel" @default.
- Q91809258 P2093 "Denis Moro-Sibilot" @default.
- Q91809258 P2093 "Eric Pichon" @default.
- Q91809258 P2093 "Fabrice Barlesi" @default.
- Q91809258 P2093 "Franck Morin" @default.
- Q91809258 P2093 "Gérard Zalcman" @default.
- Q91809258 P2093 "Julien Mazieres" @default.
- Q91809258 P2093 "Olivier Molinier" @default.
- Q91809258 P2093 "Olivier Raffy" @default.
- Q91809258 P2093 "Patrick Dumont" @default.
- Q91809258 P2093 "Patrick-Aldo Renault" @default.
- Q91809258 P2093 "Sandrine Hiret" @default.
- Q91809258 P2093 "Sylvestre Le Moulec" @default.
- Q91809258 P304 "27-36" @default.
- Q91809258 P31 Q13442814 @default.
- Q91809258 P356 "10.1016/J.EJCA.2020.02.022" @default.
- Q91809258 P478 "131" @default.
- Q91809258 P577 "2020-04-07T00:00:00Z" @default.
- Q91809258 P698 "32276179" @default.
- Q91809258 P921 Q413299 @default.
- Q91809258 P921 Q420436 @default.
- Q91809258 P921 Q423762 @default.